Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases.

Purpose: The CD40-CD40L pathway is a promising treatment target for autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus and lupus nephritis. The safety, pharmacokinetics and pharmacodynamics of BI 655064, a novel humanised antagonistic anti-CD40 monoclonal antibody, were i...

Descripción completa

Detalles Bibliográficos

Publicado en:	European Journal of Clinical Pharmacology Vol. 74; no. 2; pp. 161 - 170
Autores principales:	Albach, Fredrik, Wagner, Frank, Hüser, Andreas, Igel, Julia, Joseph, David, Hilbert, James, Schoelch, Corinna, Padula, Steven, Steffgen, Jürgen
Formato:	research tables/charts randomized controlled trial Journal Article
Publicado:	Springer Nature Feb2018
Acceso en línea:	Ver este registro en EBSCOhost